3 Possible Catalysts for Inovio Pharmaceuticals in 2014

Inovio Pharmaceuticals could be a stock to watch in 2014 for these three reasons.

Feb 12, 2014 at 4:59PM

There's a real buzz around Inovio Pharmaceuticals (NASDAQ:INO).

Indeed, shares have have risen from $0.72 one year ago to $2.82 at the time of writing. That's a gain of 291%. I don't need to tell you that the major U.S. indices posted gains that were only fractions of that amount over the same period.

Moreover, much of that gain has come the last eight months or so, and the buzz surrounding Inovio Pharmaceuticals culminated in the company being invited by the New York Stock Exchange to ring the opening bell on Feb. 12.

Much of the hype surrounding Inovio has to do with the future -- more specifically, the potential catalysts for the stock. Here are three that could be worth keeping an eye on throughout 2014 (this list is not exhaustive).

1. The exclusive worldwide partnership with Roche to develop and commercialize products from Inovio Pharmaceuticals' prostate cancer and hepatitis B immunotherapy programs appears to be making encouraging progress. Although Inovio remains tight-lipped about the identity of other large pharmaceutical companies with whom it is in discussions, those discussions are ongoing and further news is likely to surface during the year.

2. Although Inovio manages a relatively broad portfolio of immunotherapies, its lead program remains focused on cancer immunotherapy. Efficacy data from the phase 2 trial of this program is due to be released in the second or third quarter of this year and could have a major impact on the stock price.

3. Inovio expects to update the market throughout the year on both its prostate cancer and hepatitis B therapies with Roche, but also initiate several new clinical trials for cancer immunotherapies. Updates from these trials could impact the stock price, too.

Of course, Inovio Pharmaceuticals isn't the only stock garnering some buzz in 2014. Other health care companies that are focused on immunotherapies have also seen their share prices deliver notable movements, with two obvious examples being ImmunoCellular Therapeutics (NYSE MKT:IMUC) and Galena Biopharma (NASDAQ:GALE).

ImmunoCellular Therapeutics has seen its share price move from roughly $0.92 at the start of the year to $1.21 as of the closing bell Wednesday, although it should be noted that it reached as high as $1.56 before pulling back. As with Inovio, the company has numerous potential catalysts for the year ahead, including a meeting with the FDA to discuss phase 2 results for its lead product candidate, the brain cancer treatment ICT-107, as well as a decision from the European Medicines Agency on whether ICT-107 will be granted an orphan designation.

Meanwhile, Galena Biopharma's share price is at the same level as it was on New Year's Eve. However, this doesn't tell the whole story because the stock has been as much as 50% higher as a result of the company's deal to purchase Mills Pharmaceuticals for $200 million, a strategic partnership for breast cancer drug NeuVax in India, and positive updates surrounding a phase 2 trial for cancer immunotherapy GALE-301.

It could be worth keeping an eye on all three immunotherapy-focused companies. With the buzz surrounding its current share price and the three catalysts mentioned above, 2014 could be a very interesting year for Inovio Pharmaceuticals in particular.

The Motley Fool's Top Stock For 2014

There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Peter Stephens has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers